• The clinical results of therapy with isoniazid for multiple sclerosis, while effecting subjective and objective improvement in a large percentage of cases, cannot be considered significant. New exacerbations continued to occur whether or not isoniazid therapy was continued. It has been established, however, that it is possible to evaluate therapy in this disease, in a reasonably short time, if the disease is manifested by progressing dysfunction, if the study is done on concurrently observed patients with comparable illnesses, and if a double-blind procedure is utilized.
Kurtzke JF, Berlin L. ISONIAZID IN TREATMENT OF MULTIPLE SCLEROSIS. JAMA. 1957;163(3):172–174. doi:10.1001/jama.1957.02970380014005
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: